<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1021d93b-7ea4-4451-9c13-06b8262b1976"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use WELIREG safely and effectively. See full prescribing information for WELIREG.<br/>
      <br/>WELIREG<sup>Â®</sup> (belzutifan) tablets, for oral use<br/>Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250415"/>
   <setId root="13e15ee0-d679-4fa9-9430-e2e2170474da"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="118446553"/>
            <name>Merck Sharp &amp; Dohme LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8b706a9e-18f4-40c6-ab00-15fc8a6a4e7c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250415"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0006-5331" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>WELIREG</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>belzutifan</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7K28NB895L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BELZUTIFAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7K28NB895L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BELZUTIFAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6N003M473W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4AQJ3LG584" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0006-5331-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210813"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0006-5331-58" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230621"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0006-5331-59" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230621"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215383" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210813"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">177</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="SBW">
               <id root="68aa9652-3ff2-45c0-8efa-893dcd23e936"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING Section"/>
               <title>WARNING: EMBRYO-FETAL TOXICITY</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Exposure to WELIREG during pregnancy can cause embryo-fetal harm.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Verify pregnancy status prior to the initiation of WELIREG.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: EMBRYO-FETAL TOXICITY</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Exposure to WELIREG during pregnancy can cause embryo-fetal harm.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Verify pregnancy status prior to the initiation of WELIREG.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="724d6a3f-eb2f-4c4b-b2a6-3000d410cd09"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="75%" align="left" valign="top"/>
                           <col width="25%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage, Advanced Renal Cell Carcinoma (RCC) (<linkHtml href="#S1.2">1.2</linkHtml>)</td>
                                 <td>04/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2d54d072-3faf-4c11-b371-3636a84d43b0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WELIREG is a hypoxia-inducible factor inhibitor indicated:</paragraph>
                        <paragraph>
                           <content styleCode="underline">von Hippel-Lindau (VHL) disease</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Advanced Renal Cell Carcinoma (RCC)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="f1c87ab9-4e50-4d59-be29-153dad368fcf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 von Hippel-Lindau (VHL) disease</title>
                     <text>
                        <paragraph>WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="800ec92e-8887-48f6-80f6-6588d4a66b9f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.2 Advanced Renal Cell Carcinoma (RCC)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">WELIREG is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="34ab225c-43f3-4463-8b06-95e5d2eb0a29"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                The recommended dosage of WELIREG is 120 mg administered orally once daily with or without food. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3869a5df-9ba0-4156-abe6-d4e5f3c1a81c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of WELIREG is 120 mg administered orally once daily until disease progression or unacceptable toxicity. WELIREG should be taken at the same time each day and may be taken with or without food.</paragraph>
                        <paragraph>
                 Advise patients to swallow tablets whole. Do not chew, crush, or split WELIREG prior to swallowing.
                </paragraph>
                        <paragraph>
                 If a dose of WELIREG is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for WELIREG the next day. Do not take extra tablets to make up for the missed dose.
                </paragraph>
                        <paragraph>
                 If vomiting occurs any time after taking WELIREG, do not retake the dose. Take the next dose on the next day.
                </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="1e8dc08e-6a87-4219-8233-d57855dd3f5a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Dosage modifications for WELIREG for adverse reactions are summarized in <linkHtml href="#Table1">Table 1</linkHtml>.</paragraph>
                        <paragraph>The recommended dose reductions are:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>First dose reduction: WELIREG 80 mg orally once daily</item>
                           <item>Second dose reduction: WELIREG 40 mg orally once daily</item>
                           <item>Third dose reduction: Permanently discontinue</item>
                        </list>
                        <table ID="Table1" width="80%">
                           <caption>Table 1: Recommended Dosage Modifications for Adverse Reactions</caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">Adverse Reaction</th>
                                 <th styleCode="Rrule" align="center">Severity</th>
                                 <th styleCode="Rrule" align="center">Dosage Modification</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Botrule Lrule Rrule" valign="top">
                        Anemia <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top">Hemoglobin &lt;8 g/dL or transfusion indicated</td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold until hemoglobin â¥8g/dL.</item>
                                       <item>Resume at the same or reduced dose; or discontinue depending on the severity of anemia.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Life-threatening or urgent intervention indicated</td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold until hemoglobin â¥8g/dL.</item>
                                       <item>Resume at a reduced dose or permanently discontinue.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Botrule Lrule Rrule" valign="top">
                        Hypoxia <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top">
                        Decreased oxygen saturation with exercise (e.g., pulse oximeter  &lt;88%)
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Consider withholding until resolved.</item>
                                       <item>Resume at the same dose or at a reduced dose depending on the severity of hypoxia.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Decreased oxygen saturation at rest (e.g., pulse oximeter &lt;88% or PaO<sub>2</sub> â¤55 mm Hg) or urgent intervention indicated 
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold until resolved. </item>
                                       <item>Resume at reduced dose or discontinue depending on the severity of hypoxia.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Life-threatening or recurrent symptomatic hypoxia
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item> Permanently discontinue.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Botrule Lrule Rrule" valign="top">
                        Other Adverse Reactions  <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top">Grade 3</td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold dosing until resolved to â¤ Grade 2.</item>
                                       <item>Consider resuming at a reduced dose (reduce by 40 mg).</item>
                                       <item> Permanently discontinue upon recurrence of Grade 3.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Grade 4
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="07ddf5e6-1193-46c4-a33e-8436dd83bf6a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets: 40 mg, blue, oval shaped, film-coated, debossed with â177â on one side and plain on the other side. </paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 40 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4f5124cb-b6f5-4752-8cde-f3ed666cb7b6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="a8622873-f683-4ec5-83b0-6b540be88051"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Anemia</content>: Monitor for anemia before initiation of and periodically throughout treatment with WELIREG.(<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Withhold WELIREG until hemoglobin â¥8g/dL, then resume at the same or reduced dose or discontinue. For life threatening anemia, or for anemia requiring urgent intervention, withhold WELIREG until hemoglobin â¥8g/dL and resume at a reduced dose or permanently discontinue WELIREG. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypoxia</content>: Monitor oxygen saturation before initiation of, and periodically throughout, treatment with WELIREG. For hypoxia at rest, withhold until resolved, resume at reduced dose, or discontinue depending on severity. For life-threatening hypoxia, permanently discontinue WELIREG. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="edfabe38-7a22-457d-a1e0-006b9ee13e40"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Anemia</title>
                     <text>
                        <paragraph>WELIREG can cause severe anemia that can require blood transfusion.</paragraph>
                        <paragraph>Monitor for anemia before initiation of, and periodically throughout, treatment with WELIREG. Transfuse patients as clinically indicated. For patients with hemoglobin &lt;8g/dL, withhold WELIREG until â¥8g/dL, then resume at the same or reduced dose or permanently discontinue WELIREG, depending on the severity of anemia. For life threatening anemia or when urgent intervention is indicated, withhold WELIREG until hemoglobin â¥8g/dL, then resume at a reduced dose or permanently discontinue WELIREG <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">von Hippel-Lindau (VHL) disease</content>
                        </paragraph>
                        <paragraph>In LITESPARK-004, decreased hemoglobin occurred in 93% of patients and 7% had Grade 3 events <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Median time to onset of anemia was 31 days (range: 1 day to 8.4 months).</paragraph>
                        <paragraph>The safety of erythropoiesis stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG has not been established. Randomized controlled trials in patients with cancer receiving myelosuppressive chemotherapy with ESAs have shown that ESAs increased the risks of death and serious cardiovascular reactions, and decreased progression-free survival and/or overall survival. See the prescribing information for ESAs for more information.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Advanced Renal Cell Carcinoma (RCC)</content>
                        </paragraph>
                        <paragraph>In LITESPARK-005, decreased hemoglobin occurred in 88% of patients and 29% had Grade 3 events <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Median time to onset of anemia was 29 days (range: 1 day to 16.6 months). Of the patients with anemia, 22% received transfusions only, 20% of patients received ESAs only and 12% received both transfusion and ESAs.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="37ecb35f-30bc-4c85-b9bb-d0ab3c7b89a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypoxia</title>
                     <text>
                        <paragraph>WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Monitor oxygen saturation before initiation of, and periodically throughout, treatment with WELIREG. For decreased oxygen saturation with exercise (e.g., pulse oximeter &lt;88% or P<sub>a</sub>O<sub>2</sub> â¤55 mm Hg), consider withholding WELIREG until pulse oximetry with exercise is greater than 88%, then resume at the same dose or at a reduced dose. For decreased oxygen saturation at rest (e.g., pulse oximeter &lt;88% or PaO2 â¤55 mm Hg) or urgent intervention indicated, withhold WELIREG until resolved and resume at a reduced dose or discontinue. For life-threatening hypoxia or for recurrent symptomatic hypoxia, permanently discontinue WELIREG <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>Advise patients to report signs and symptoms of hypoxia immediately to a healthcare provider. </paragraph>
                        <paragraph>
                           <content styleCode="underline">von Hippel-Lindau (VHL) disease</content>
                        </paragraph>
                        <paragraph>In LITESPARK- 004, hypoxia occurred in 1.6% of patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Advanced Renal Cell Carcinoma (RCC)</content>
                        </paragraph>
                        <paragraph>In LITESPARK- 005, hypoxia occurred in 15% of patients and 10% had Grade 3 events <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Of the patients with hypoxia, 69% were treated with oxygen therapy. Median time to onset of hypoxia was 30.5 days (range: 1 day to 21.1 months).</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="f4dcac62-8205-4e83-bfd5-2e23fdb5e5b7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings in animals, WELIREG can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of belzutifan to pregnant rats during the period of organogenesis caused embryo-fetal lethality, reduced fetal body weight, and fetal skeletal malformations at maternal exposures â¥0.2 times the human exposures (AUC) at the recommended dose of 120 mg daily.</paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose, since WELIREG can render some hormonal contraceptives ineffective <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content> Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="8aa04cba-3cb1-4668-b962-230f144ff2a8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Anemia <content styleCode="italics">[see<linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hypoxia <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">VHL disease</content>: Most common (â¥25%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea. (<linkHtml href="#S6.1">6.1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Advanced RCC</content>: Most common (â¥25%) adverse reactions, including laboratory abnormalities were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase. (<linkHtml href="#S6.1">6.1</linkHtml>) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or <content styleCode="underline">
                                 <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ca737f85-153a-4e7d-8955-4211eaecced1"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">von Hippel-Lindau (VHL) disease</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">LITESPARK-004</content>
                        </paragraph>
                        <paragraph>
                  The safety of WELIREG was evaluated in an open-label clinical trial (LITESPARK-004) in 61 patients with VHL disease who had at least one measurable solid tumor localized to the kidney <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Patients received WELIREG 120 mg orally once daily. The median duration of exposure to WELIREG was 68 weeks (range: 8.4 to 104.7 weeks).
                </paragraph>
                        <paragraph>
                  Serious adverse reactions occurred in 15% of patients who received WELIREG, including anemia, hypoxia, anaphylaxis reaction, retinal detachment, and central retinal vein occlusion (1 patient each).</paragraph>
                        <paragraph>Permanent discontinuation of WELIREG due to adverse reactions occurred in 3.3% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG were dizziness and opioid overdose (1.6% each).</paragraph>
                        <paragraph>Dosage interruptions of WELIREG due to an adverse reaction occurred in 39% of patients. Adverse reactions which required dosage interruption in &gt;2% of patients were fatigue, decreased hemoglobin, anemia, nausea, abdominal pain, headache, and influenza-like illness.</paragraph>
                        <paragraph>Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients. The most frequently reported adverse reaction which required dose reduction was fatigue (7%).</paragraph>
                        <paragraph>The most common (â¥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.</paragraph>
                        <paragraph>
                           <linkHtml href="#table2">Table 2</linkHtml> summarizes the adverse reactions reported in patients treated with WELIREG in LITESPARK-004.</paragraph>
                        <table ID="table2" width="80%">
                           <caption>Table 2: Adverse Reactions Occurring in â¥10% of Patients Who Received WELIREG in LITESPARK-004</caption>
                           <col width="40%" align="left" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" rowspan="2">Adverse Reaction</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">WELIREG<br/>(n=61)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" align="center">All Grades<footnote ID="t2f1">Graded per NCI CTCAE v4.0</footnote>
                                    <br/>(%)</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grade 3-4<br/>(%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">General</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Fatigue<footnote ID="t2f2">Includes other related terms</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">64</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Nervous system</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Headache<footnoteRef IDREF="t2f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">39</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Dizziness<footnoteRef IDREF="t2f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">38</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Nausea</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">31</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Constipation</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">13</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Abdominal pain<footnoteRef IDREF="t2f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">13</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Eye Disorders</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Visual impairment<footnote ID="t2f3">Includes visual impairment, vision blurred, central retinal vein occlusion and retinal detachment</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">21</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">3.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Infections</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Upper respiratory tract infection <footnoteRef IDREF="t2f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">21</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Respiratory, Thoracic and Mediastinal</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Dyspnea</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">20</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Musculoskeletal and Connective Tissue</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Arthralgia
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">18</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0
                      </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Myalgia</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">16</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Vascular</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Hypertension</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">13</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">3.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Metabolism and Nutrition</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Weight increased</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">12</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.6</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#table3">Table 3</linkHtml> summarizes the laboratory abnormalities in LITESPARK-004.</paragraph>
                        <table ID="table3" width="80%">
                           <caption>Table 3: Select Laboratory Abnormalities (â¥10%) That Worsened from Baseline in Patients Who Received WELIREG in LITESPARK-004</caption>
                           <col width="40%" align="left" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <col width="30%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" rowspan="2" align="center">Laboratory Abnormality<footnote ID="t3f1">The denominator used to calculate the rate is based on all patients in the safety analysis population.</footnote>
                                 </th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">WELIREG<br/>(n=61)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" align="center">Grades 1-4<br/>%</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grades 3-4<br/>%</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="3">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Decreased hemoglobin
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">93</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Decreased leukocytes
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">11</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="3">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Increased creatinine
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">64</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Increased glucose
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">34</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">4.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                       Â Â Increased ALT
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">20</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Increased AST
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">16</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Decreased calcium (corrected)
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">10</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                        Â Â Decreased phosphate
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">10</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.6</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Advanced Renal Cell Carcinoma (RCC)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline italics">LITESPARK-005</content>
                        </paragraph>
                        <paragraph>The safety of WELIREG was evaluated in a randomized, active-controlled study (LITESPARK- 005) in 732 patients with advanced RCC with a clear cell component that has progressed after prior PD-1 or PD-L1 checkpoint inhibitor and VEGF receptor targeted therapies <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. Patients received 120 mg WELIREG (n=372) or 10 mg everolimus (n=360) by oral administration once daily. The median duration of exposure to WELIREG was 7.6 months (range 0.1 to 28.5 months).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 38% of patients who received WELIREG. Serious adverse reactions in â¥2% of patients treated with WELIREG were hypoxia (7%), anemia (5%), pneumonia (3.5%), hemorrhage (3%), and pleural effusion (2.2%). Fatal adverse reactions occurred in 3.2% of patients who received WELIREG, including sepsis (0.5%) and hemorrhage (0.5%).</paragraph>
                        <paragraph>Permanent discontinuation of WELIREG due to adverse reactions occurred in 6% of patients. Adverse reactions which resulted in permanent discontinuation (â¥0.5%) of WELIREG were hypoxia (1.1%), anemia (0.5%), and hemorrhage (0.5%).</paragraph>
                        <paragraph>Dosage interruptions of WELIREG due to an adverse reaction occurred in 39% of patients. Adverse reactions which required dosage interruption in â¥2% of patients were anemia (8%), hypoxia (5%), COVID-19 (4.3%), fatigue (3.2%), and hemorrhage (2.2%).</paragraph>
                        <paragraph>Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients. Adverse reactions which required dose reduction in â¥1% of patients were hypoxia (5%) and anemia (3.2%).</paragraph>
                        <paragraph>The most common (â¥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase.</paragraph>
                        <paragraph>
                           <linkHtml href="#table4">Table 4</linkHtml> summarizes the adverse reactions in LITESPARK-005.</paragraph>
                        <table ID="table4" width="80%">
                           <caption>Table 4: Adverse Reactions (â¥10%) in Patients with Advanced RCC Receiving WELIREG in LITESPARK-005</caption>
                           <col width="30%" align="left" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="18%" align="center" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="18%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="middle" align="left" rowspan="2">Adverse Reaction</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">WELIREG<br/>(n=372)</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">Everolimus<br/>(n=360)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" align="center">All Grades<footnote ID="t40f1">Graded per NCI CTCAE v5.0</footnote>
                                    <br/>(%)</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grade 3-4<br/>(%)</th>
                                 <th styleCode="Botrule Lrule Rrule" valign="top">All Grades<footnoteRef IDREF="t40f1"/>
                                    <br/>(%)</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grade 3-4<br/>(%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">General</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="4"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Fatigue<footnote ID="t40f2">Includes other related terms</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">43</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">3.2</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">41</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Edema<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">20</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.5</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">23</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Musculoskeletal and Connective Tissue</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Musculoskeletal Pain<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">34</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">27</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Gastrointestinal</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Nausea
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">17</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.5</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">11</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Constipation
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">15</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Vomiting
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">11</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Diarrhea<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">11</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.3</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">19</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Abdominal Pain<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">10</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Respiratory, Thoracic, and Mediastinal</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Dyspnea<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">16</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.6</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">16</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Hypoxia
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">15</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">10</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.4</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Metabolism and Nutrition</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased Appetite
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">13</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">16</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Nervous Systems</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Headache<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">12</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.5</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Dizziness<footnoteRef IDREF="t40f2"/>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">11</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.9</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt;10% of patients who received WELIREG in LITESPARK-005 included hemorrhage (9%) [including intracranial/cerebral hemorrhage (0.8%)], rash (8%), hypertension (6%), visual impairment [including vision blurred (4%), visual acuity decreased (1.1%), visual impairment (0.5%), and retinal detachment (0.3%)] (6%) and increased weight (5%).</paragraph>
                        <paragraph>
                           <linkHtml href="#table5">Table 5</linkHtml> summarizes the laboratory abnormalities in LITESPARK-005.</paragraph>
                        <table ID="table5" width="80%">
                           <caption>Table 5: Select Laboratory Abnormalities (â¥20%) That Worsened from Baseline In Patients with Advanced RCC who Received WELIREG in LITESPARK-005</caption>
                           <col width="30%" align="left" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="18%" align="center" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="18%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="middle" align="left" rowspan="2">Laboratory Test<footnote ID="t50f1">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available WELIREG (range: 359 to 366 patients), and everolimus (range: 351 to 356 patients).</footnote>
                                 </th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">WELIREG</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center" colspan="2">Everolimus</th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" valign="top" align="center">All Grades<footnote ID="t50f2">Graded per NCI CTCAE v5.0</footnote>
                                    <br/>%</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grades 3-4<br/>%</th>
                                 <th styleCode="Botrule Lrule Rrule" valign="top">All Grades<footnoteRef IDREF="t50f2"/>
                                    <br/>%</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Grades 3-4<br/>%</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased hemoglobin
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">88</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">29</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">76</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">17</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased lymphocytes
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">34</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">8</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">53</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">20</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="5">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Increased creatinine
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">34</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">4.7</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">43</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">5.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Increased alanine aminotransferase
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">32</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.2</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">40</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased sodium
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">31</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.6</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">36</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Increased potassium
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">29</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.5</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">20</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Increased aspartate aminotransferase
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">27</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2.2</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">38</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased glucose
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">22</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">19</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Decreased calcium
                      </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">21</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">1.1</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">45</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">3.1</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="0890bb83-7ae5-408f-bd26-cbffad8a53a8"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">UGT2B17 or CYP2C19 Inhibitors:</content> Monitor for signs and symptoms of anemia and hypoxia and reduce the dosage of WELIREG as recommended. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="c1fb8460-b6c2-4280-911c-ad8ff35eb95e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effects of Other Drugs on WELIREG</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">UGT2B17 or CYP2C19 Inhibitors</content>
                        </paragraph>
                        <paragraph>Coadministration of WELIREG with inhibitors of UGT2B17 or CYP2C19 increases plasma exposure of belzutifan <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S12.3"> Clinical Pharmacology (12.3</linkHtml>, <linkHtml href="#S12.5">12.5)</linkHtml>]</content>, which may increase the incidence and severity of adverse reactions of WELIREG. Monitor for anemia and hypoxia and reduce the dosage of WELIREG as recommended <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S2.2"> Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.1"> Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2)</linkHtml>, <linkHtml href="#S6"> Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="4b3fe12b-15b2-415c-bb63-ecdd8393c155"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of WELIREG on Other Drugs</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Sensitive CYP3A4 Substrates</content>
                        </paragraph>
                        <paragraph>Coadministration of WELIREG with CYP3A4 substrates decreases concentrations of CYP3A substrates <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce the efficacy of these substrates. The magnitude of this decrease may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolizers <content styleCode="italics">[see <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>].</content> Avoid coadministration of WELIREG with sensitive CYP3A4 substrates, for which minimal decrease in concentration may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hormonal Contraceptives</content>
                        </paragraph>
                        <paragraph>Coadministration of WELIREG with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="4d825520-e546-42e7-8dc7-90be0a162406"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Infertility</content>: May impair fertility in males and females. (<linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="2197babb-4361-440e-8f64-c4831e817a92"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>
                  Based on findings in animal studies, WELIREG can cause fetal harm when administered to a pregnant woman. There are no available data on the use of WELIREG in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of belzutifan to pregnant rats during the period of organogenesis caused embryo-fetal lethality, reduced fetal body weight, and fetal skeletal malformations at maternal exposures â¥0.2 times the human exposure (AUC) at the recommended dose of 120 mg daily (<content styleCode="italics">see <linkHtml href="#Data">Data</linkHtml>
                           </content>). Advise pregnant women and females of reproductive potential of the potential risk to a fetus. 
                </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2â4% and 15â20%, respectively.</paragraph>
                        <paragraph ID="Data">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In a pilot embryo-fetal development study, pregnant rats received oral doses of 6, 60, or 200 mg/kg/day of belzutifan during the period of organogenesis. Belzutifan caused embryo-fetal lethality at doses â¥60 mg/kg/day (approximately 1 time the human exposure at the recommended dose based on AUC). Reduced fetal body weights, fetal rib malformations, and reduced skeletal ossification occurred at doses of 6 and 60 mg/kg/day (approximately â¥0.2 times the human exposure at the recommended dose based on AUC).</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="dab6a366-cefa-42eb-8841-6462e30598a0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>
                  There are no data on the presence of belzutifan or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with WELIREG and for 1 week after the last dose.
                </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="ba1a6abe-7d42-44f4-a72b-f05cd556a66c"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>WELIREG can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S8.1"> Use in Specific Populations (8.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating treatment with WELIREG. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose. WELIREG can render some hormonal contraceptives ineffective <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Based on findings in animals, WELIREG may impair fertility in males and females of reproductive potential <content styleCode="italics"> [see</content>
                           <content styleCode="italics">
                              <linkHtml href="#S13.1"> Nonclinical Toxicology (13.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. The reversibility of the effect on fertility is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="d1da1316-6d14-44f3-83de-b58ded58b2f9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of WELIREG have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="426734a1-a3cb-4d83-b4c5-64658e5a017e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the patients who received WELIREG in LITESPARK-004, 3.3% were â¥65 years old <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content> Clinical trials of WELIREG in patients with VHL did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.</paragraph>
                        <paragraph>Of the 372 patients who received WELIREG for advanced RCC in LITESPARK-005, 62% of patients younger than 65 years, 28% of patients were 65 to 74 years, and 10% were 75 years and over. No overall difference in efficacy was reported between patients who were â¥65 years of age and younger patients. Dose interruptions occurred in 48% of patients â¥65 years of age and in 34% of younger patients. Dose reductions occurred in 18% of patients â¥65 years of age and in 10% of younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6cc5b455-6c6f-44cb-a472-55d3de57310f"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dosage modification of WELIREG is recommended in patients with mild (eGFR 60-89 mL/min/1.73 m<sup>2</sup> estimated by MDRD) and moderate (eGFR 30-59 mL/min/1.73 m<sup>2</sup>) renal impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> WELIREG has not been studied in patients with severe (eGFR 15-29 mL/min/1.73 m<sup>2</sup>) renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="858b1d5a-08a8-4a6d-bc44-7c19536cb526"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage modification of WELIREG is recommended in patients with mild [total bilirubin â¤ upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt;1 to 1.5 x ULN and any AST] hepatic impairment. WELIREG has not been studied in patients with moderate or severe hepatic impairment (total bilirubin &gt;1.5 x ULN and any AST) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.8">
                     <id root="b967d2cc-daaf-41c1-8d58-7fdf4411ac75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.8 Dual UGT2B17 and CYP2C19 Poor Metabolizers</title>
                     <text>
                        <paragraph>Patients who are dual UGT2B17 and CYP2C19 poor metabolizers have higher belzutifan exposures, which may increase the incidence and severity of adverse reactions of WELIREG. Closely monitor for adverse reactions in patients who are dual UGT2B17 and CYP2C19 poor metabolizers <content styleCode="italics">[see <linkHtml href="#S5">Warnings and Precautions (5)</linkHtml>, <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>, <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="3a6630ac-7c2e-480a-aff1-0ff1e5fe3a4d"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There is no specific treatment for WELIREG overdose. In cases of suspected overdose, withhold WELIREG and institute supportive care. Grade 3 hypoxia occurred at dosages of 120 mg twice a day and Grade 4 thrombocytopenia occurred at dosages of 240 mg once daily (approximately 2 times the recommended dosage).</paragraph>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="b84f21c1-e938-4b16-ac7c-db9c2c064070"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Belzutifan is an inhibitor of hypoxia-inducible factor-2Î± (HIF-2Î±). The chemical name of belzutifan is 3-[[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluorobenzonitrile. The molecular formula is C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>4</sub>S and the molecular weight is 383.34 Daltons. The chemical structure is:</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <tbody>
                        <tr>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM01"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Belzutifan is a white to light brown powder that is soluble in acetonitrile, dimethoxyethane, and acetone, sparingly soluble in ethyl acetate, very slightly soluble in isopropanol and toluene, and insoluble in water.</paragraph>
                  <paragraph>WELIREG is supplied as blue, film-coated tablets for oral use containing 40 mg of belzutifan together with croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide, as inactive ingredients. In addition, the film-coating contains FD&amp;C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM01">
                     <text>image description</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="welireg-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="0a202f0d-17e5-4a7d-8d4c-243263b20174"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="S12.1">
                     <id root="804be067-459b-4ba5-b232-04cdc48e2802"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2Î±). HIF-2Î± is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2Î± is targeted for ubiquitin-proteasomal degradation by VHL protein. Lack of functional VHL protein results in stabilization and accumulation of HIF-2Î±. Upon stabilization, HIF-2Î± translocates into the nucleus and interacts with hypoxia-inducible factor 1 beta (HIF-1Î²) to form a transcriptional complex that induces expression of downstream genes, including genes associated with cellular proliferation, angiogenesis, and tumor growth. Belzutifan binds to HIF-2Î±, and in conditions of hypoxia or impairment of VHL protein function, belzutifan blocks the HIF-2Î±-HIF-1Î² interaction, leading to reduced transcription and expression of HIF-2Î± target genes. In vivo, belzutifan demonstrated anti-tumor activity in mouse xenograft models of renal cell carcinoma.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="029dedc5-369b-4224-a07f-d54efe2db6e5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Reductions in plasma levels of erythropoietin (EPO) were observed to be dose- and exposure-dependent at dosages up to 120 mg once daily. The maximum EPO suppression occurred following 2 weeks of consecutive dosing of WELIREG (mean percent decrease from baseline of approximately 60%). Mean EPO levels gradually returned to baseline values after 12 weeks of treatment.</paragraph>
                        <paragraph>The incidence of Grade 3 anemia increased with higher belzutifan exposure in patients with baseline hemoglobin levels &lt;12 g/dL <content styleCode="italics">[see <linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At the recommended dosage, WELIREG does not cause large mean increases (i.e., &gt;20 msec) in the QT interval. </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0c28b3b0-0287-48fd-808d-080e67eddf8a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The C<sub>max</sub> and AUC of belzutifan increase proportionally over a dose range of 20 mg to 120 mg WELIREG (0.17 to 1 times the approved recommended dose). The estimated geometric mean steady-state (CV%) C<sub>max</sub> is 1.5 Î¼g/mL (45%) and AUC<sub>0-24h</sub> is 20.4 Î¼gâ¢hr/mL (62%) in patients treated with 120 mg WELIREG. Steady state is reached after approximately 3 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The median T<sub>max</sub> occurs at 1 to 2 hours after WELIREG administration. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>A high-fat, high-calorie meal (total calories approximately 1000 kcal, 56 g fat, 55 g carbohydrate, and 31 g protein) delayed T<sub>max</sub> by approximately 2 hours with no clinically meaningful effect on C<sub>max</sub>, and AUC of belzutifan.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The estimated mean (CV%) volume of distribution is 119 L (28%) Plasma protein binding of belzutifan is 45%. The blood-to-plasma concentration ratio of belzutifan is 0.88.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The estimated mean (CV%) clearance is 6.0 L/hr (58%) and the mean elimination half-life is 14 hrs.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Belzutifan is primarily metabolized by UGT2B17 and CYP2C19 and to a lesser extent by CYP3A4 <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following oral administration of radiolabeled belzutifan to healthy subjects, approximately 49.6% of the dose was excreted in urine and 51.7% in feces (primarily as inactive metabolites).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>Patients who are poor metabolizers of UGT2B17 and CYP2C19 had higher belzutifan AUC <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>There were no clinically significant differences in the pharmacokinetics of belzutifan based on age (19 to 90 years), sex, ethnicity (non-Hispanic, Hispanic), race (White, Black, Asian, Native American, Pacific Islander), body weight (42 to 166 kg), mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m<sup>2</sup> estimated by MDRD), or mild hepatic impairment (total bilirubin â¤ ULN with AST &gt; ULN or total bilirubin &gt; ULN to 1.5 x ULN with any AST). The effect of severe renal impairment (eGFR 15-29 mL/min/1.73 m<sup>2</sup>) and moderate to severe hepatic impairment (total bilirubin &gt; 1.5 x ULN and any AST) have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Belzutifan on CYP3A Substrates:</content> Coadministration of WELIREG 120 mg once daily with midazolam (a sensitive CYP3A4 substrate) decreased the midazolam AUC by 40% and the C<sub>max</sub> by 34%. Midazolam AUC is predicted to decrease up to 70% in patients with higher belzutifan concentrations (e.g., dual poor metabolizers) <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzymes: </content>Belzutifan does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.
                </paragraph>
                        <paragraph>
                  Belzutifan does not induce CYP1A2 or CYP2B6.
                </paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems: </content>Belzutifan is a substrate of P-gp, OATP1B1, and OATP1B3, but is not a substrate of BCRP.
                </paragraph>
                        <paragraph>
                  Belzutifan inhibits MATE2K. Belzutifan does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, or MATE1.
                </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="d5d605ab-a03c-412f-8d51-2fa4e7c1223a"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>Patients who are UGT2B17, CYP2C19, or dual UGT2B17 and CYP2C19 poor metabolizers are estimated to have 2.5-, 1.3-, or 3.2-fold higher belzutifan steady state AUC<sub>0-24h</sub>, respectively compared to patients who are UGT2B17 normal (extensive) metabolizers and CYP2C19 non-poor (ultrarapid, rapid, normal, and intermediate) metabolizers <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>UGT2B17 poor metabolizers who are homozygous for the UGT2B17*2 allele have no UGT2B17 enzyme activity. CYP2C19 poor metabolizers (such as *2/*2, *3/*3, *2/*3) have significantly reduced or absent CYP2C19 enzyme activity. Approximately 15% of White, 6% of Black or African American, and up to 77% of certain Asian populations are UGT2B17 poor metabolizers. Approximately 2% of White, 5% of Black or African American, and up to 19% of certain Asian populations are CYP2C19 poor metabolizers. Approximately 0.4% of White, 0.3% of Black or African American, and up to 15% of certain Asian populations are dual UGT2B17 and CYP2C19 poor metabolizers.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3ce4556e-e4dd-4c26-be51-eeaeb8097506"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="S13.1">
                     <id root="df45fd22-c111-47c0-b16b-85c3de2b9865"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                 Carcinogenicity studies have not been conducted with belzutifan.
                </paragraph>
                        <paragraph>Belzutifan was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay. Belzutifan was not clastogenic in either an in vitro micronucleus assay or an in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>Fertility studies in animals have not been conducted with belzutifan. In repeat-dose toxicity studies up to 3-month duration, belzutifan-related findings included degeneration/atrophy of testes and hypospermia and cellular debris of the epididymis in rats administered â¥2 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose of 120 mg daily). Findings in testes and epididymis were associated with decreased sperm count and motility and abnormal sperm morphology at â¥6 mg/kg/day (approximately 0.2 times the human exposure at the recommended dose of 120 mg daily) and did not reverse by the end of the recovery period. Belzutifan had no adverse effects on female reproductive organs in repeat-dose toxicity studies up to 3-month duration; however, belzutifan caused embryo-fetal lethality (post-implantation loss) in pregnant rats given oral doses â¥60 mg/kg/day (approximately 1 time the human exposure at the recommended dose based on AUC) during the period of organogenesis <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Population (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="1cf80117-2ebd-4862-adec-4aec58f34eca"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="S14.1">
                     <id root="647ead16-536b-4453-b0f5-48ec6f0362f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 von Hippel-Lindau (VHL) disease</title>
                     <text>
                        <paragraph>The efficacy of WELIREG was evaluated in LITESPARK-004 (NCT03401788), an open-label clinical trial in 61 patients with VHL-associated RCC diagnosed based on a VHL germline alteration and with at least one measurable solid tumor localized to the kidney as defined by response evaluation criteria in solid tumors (RECIST) v1.1. Enrolled patients had other VHL-associated tumors including CNS hemangioblastomas and pNET. CNS hemangioblastomas and pNET in these patients were diagnosed based on the presence of at least one measurable solid tumor in brain/spine or pancreas, respectively, as defined by RECIST v1.1 and identified by IRC. The study excluded patients with metastatic disease. Patients received WELIREG 120 mg once daily until progression of disease or unacceptable toxicity.</paragraph>
                        <paragraph>The study population characteristics were: median age 41 years [range 19-66 years], 3.3% age 65 or older; 53% male; 90% were White, 3.3% were Black or African-American, 1.6% were Asian, and 1.6% were Native Hawaiian or other Pacific Islander; 82% had an ECOG PS of 0, 16% had an ECOG PS of 1, and 1.6% had an ECOG PS of 2; and 84% had VHL Type I Disease. The median diameter of RCC target lesions per central independent review committee (IRC) was 2.2 cm (range 1-6.1). Median time from initial radiographic diagnosis of VHL-associated RCC tumors that led to enrollment on LITESPARK-004 to the time of treatment with WELIREG was 17.9 months (range 2.8-96.7). Seventy-seven percent of patients had prior surgical procedures for RCC. </paragraph>
                        <paragraph>The major efficacy endpoint for the treatment of VHL-associated RCC was objective response rate (ORR) measured by radiology assessment using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by IRC. Additional efficacy endpoints included duration of response (DoR), and time to response (TTR).</paragraph>
                        <paragraph>
                           <linkHtml href="#table6">Table 6</linkHtml> summarizes the efficacy results for VHL-associated RCC in LITESPARK-004.</paragraph>
                        <table ID="table6" width="77%">
                           <caption>Table 6: Efficacy Results (IRC assessment) for LITESPARK-004 for VHL-Associated RCC</caption>
                           <col width="50%" align="left" valign="bottom"/>
                           <col width="50%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="top">Efficacy Outcome Measure</th>
                                 <th styleCode="Rrule Botrule">WELIREG<br/>n=61</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">+ Denotes ongoing response.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Objective Response Rate, % (n)</content>
                                    <br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top">49% (30)<footnote ID="t4f1">All patients with a response were followed for a minimum of 18 months from the start of treatment.</footnote>
                                    <br/>(36, 62)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Complete response
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Partial response </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">49%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Duration of Response</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Median in months (range)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">Not reached (2.8+, 22+)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â % (n) with DoR â¥ 12 months</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">56% (17/30)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>For VHL-associated RCC, median TTR was 8 months (range 2.7, 19).</paragraph>
                        <paragraph>
                           <linkHtml href="#table7">Table 7</linkHtml> summarizes the efficacy results for VHL-associated pNET or CNS hemangioblastomas in LITESPARK-004. </paragraph>
                        <table ID="table7" width="80%">
                           <caption>Table 7. Efficacy Results (IRC assessment) for LITESPARK-004 for VHL-Associated Subgroups with CNS Hemangioblastomas or pNET</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule Toprule" valign="top">Endpoint</th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Patients with CNS<br/>Hemangioblastomas<br/>n=24<footnote ID="t5f1">Number of patients with measurable solid lesions, based on IRC assessment.</footnote>
                                 </th>
                                 <th styleCode="Botrule Rrule" valign="top" align="center">Patients with pNET<br/>
                                    <br/>n=12<footnoteRef IDREF="t5f1"/>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">+ Denotes ongoing response.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Objective Response Rate, % (n)</content>
                                    <br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top">63%, (15)<br/>(41, 81)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top">83% (10)<br/>(52, 98)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                     Â Â Â Complete response
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                    4% (1)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                    17% (2)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                    Â Â Â Partial response
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                    58% (14)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                    67% (8)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Duration of Response</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                                 <td styleCode="Botrule Rrule" valign="top" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                    Â Â Â Median in months (range)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                   Not reached (3.7+, 22+)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                   Not reached (11+, 19+)
                  </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                    Â Â Â % (n) with DoR â¥12 months
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                    73% (11/15)
                  </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">
                   50% (5/10)
                  </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>For VHL-associated CNS hemangioblastomas, TTR was 3.1 months (range 2.5, 11). For VHL-associated pNET, median TTR was 8.1 months (range 2.7, 11).</paragraph>
                        <paragraph>Decreases in size of CNS hemangioblastoma-associated peri-tumoral cysts and syringes were observed.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="8e4ed11d-f068-4cab-8157-06531ed56f55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Advanced Renal Cell Carcinoma (RCC)</title>
                     <text>
                        <paragraph>The efficacy of WELIREG was evaluated in LITESPARK-005 (NCT04195750), an open-label, randomized, active-controlled clinical trial in 746 patients with unresectable, locally advanced or metastatic clear cell RCC that progressed following PD-1 or PD-L1 checkpoint inhibitor and VEGF receptor targeted therapies either in sequence or in combination.</paragraph>
                        <paragraph>Patients could have received up to 3 prior treatment regimens and were required to have measurable disease per RECIST v1.1. Patients were randomized in a 1:1 ratio to receive 120 mg WELIREG or 10 mg everolimus by oral administration once daily. Randomization was stratified by IMDC risk categories (favorable versus intermediate versus poor) and number of prior VEGF receptor targeted therapies (1 versus 2-3). Patients were evaluated radiologically at Week 9 from the date of randomization, then every 8 weeks through Week 49, and every 12 weeks thereafter.</paragraph>
                        <paragraph>The study population characteristics were: median age 63 years [range 22 to 90 years], 42% age 65 or older; 78% male; 79% White; 12% Asian; 1% Black or African American; 11% Hispanic or Latino; 44% ECOG performance status 0 and 55% ECOG performance status 1. Prior therapies: 13% patients had 1 prior line of therapy, 43% had 2 prior lines of therapy and 43% had 3 prior lines of therapy; 49% received 2 to 3 prior VEGF receptor targeted therapies. Patient distribution by IMDC risk categories was 22% favorable, 66% intermediate, and 12% poor. Common sites of metastasis in patients were 65% lung, 59% lymph nodes, and 49% bone.</paragraph>
                        <paragraph>The major efficacy endpoints were Progression Free Survival (PFS) measured by BICR using RECIST v1.1 and Overall Survival (OS). Additional efficacy endpoint included objective response rate (ORR) by BICR using RECIST v1.1.</paragraph>
                        <paragraph>The trial demonstrated a statistically significant improvement in PFS for patients randomized to WELIREG compared with everolimus. <linkHtml href="#table8">Table 8</linkHtml> and <linkHtml href="#fig1">Figure 1</linkHtml> summarize the efficacy results for LITESPARK-005.</paragraph>
                        <table ID="table8" width="78%">
                           <caption>Table 8: Efficacy Results for Advanced RCC (IRC assessment) for LITESPARK-005</caption>
                           <col width="38%" align="left" valign="bottom"/>
                           <col width="24%" align="center" valign="bottom"/>
                           <col width="38%" align="center" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="top">Efficacy Outcome Measure</th>
                                 <th styleCode="Rrule Botrule">WELIREG<br/>n=374</th>
                                 <th styleCode="Rrule Botrule">Everolimus<br/>n=372</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">NS â not statistically significant</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="3">
                                    <content styleCode="bold">Progression-Free Survival (PFS)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Number of events, n (%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">257 (69%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">262 (70%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Â Â Progressive disease</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">234 (63%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">222 (60%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Â Â Death</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">23 (6%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">40 (11%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Median in months (95% CI) <footnote ID="t8f1">From product-limit (Kaplan-Meier) method for censored data</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">5.6 (3.9, 7.0)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">5.6 (4.8, 5.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Hazard ratio <footnote ID="t8f2">Based on the stratified Cox proportional hazard model.</footnote> (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center" colspan="2">0.75 (0.63, 0.90)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">p-Value <footnote ID="t8f3">One-sided p-Value based on stratified log-rank test compared with the significance boundary of 0.0021.</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center" colspan="2">0.0008</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="3">
                                    <content styleCode="bold">Overall Survival (OS)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Number of events, n (%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">254 (68%)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">259 (70%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Median in months (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">21 (18, 24)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">18 (16, 22)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Hazard ratio <footnoteRef IDREF="t8f2"/> (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center" colspan="2">0.92 (0.77, 1.10)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">p-Value<footnote ID="t8f4">Based on stratified log-rank test.</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center" colspan="2">NS</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top" colspan="3">
                                    <content styleCode="bold">Confirmed Objective Response Rate</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Number of patients with measurable disease at baseline</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">373</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">364</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">ORR % (n) (95% CI)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">22% (82) (18, 27)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">4% (13) (2, 6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Â Â Complete response</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">3% (10)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">0% (0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Â Â Partial response</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">19% (72)</td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center">4% (13)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">Â Â Â Â Â p-Value<footnote ID="t8f5">One-sided p-value based on stratified Miettinen and Nurminen (M&amp;N) method.</footnote>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top" align="center" colspan="2">&lt;0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Among the 82 patients treated with WELIREG who achieved a confirmed response based on BICR per RECIST 1.1, 25 (30%) patients had a duration of response â¥12 months.</paragraph>
                        <table ID="fig1" width="100%" styleCode="Noautorules">
                           <caption>Figure 1: Kaplan-Meier Curve for Progression-Free Survival in LITESPARK-005</caption>
                           <col width="100%" align="center" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM1"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250415"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="welireg-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="04a170fe-40ca-4334-beab-ca6216826b6c"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>WELIREG tablets are supplied as 40 mg blue, oval shaped, film-coated, debossed with â177â on one side and plain on the other side, available in: </paragraph>
                  <list listType="unordered">
                     <item>bottles of 90 tablets with child-resistant closure: NDC 0006-5331-01.</item>
                  </list>
                  <paragraph>The bottle also contains two desiccant canisters. Do not eat.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F), excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) [see USP Controlled Room Temperature]. </paragraph>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="6991a043-0900-4876-92ec-c8a0adb9010c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#MedGuide">Medication Guide</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Anemia</content>
                  </paragraph>
                  <paragraph>Inform patients that WELIREG can cause severe anemia that may require blood transfusions and that red blood cell levels will be monitored routinely during treatment. Advise patients to contact their healthcare provider if the patient experiences any symptoms suggestive of anemia<content styleCode="italics"> [see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypoxia</content>
                  </paragraph>
                  <paragraph>Inform patients that WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization; and that oxygen levels will be monitored routinely during treatment. Advise patients to contact their healthcare provider if the patient experiences any symptoms suggestive of hypoxia <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Advise pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Population (8.1)</linkHtml>]</content>. </item>
                     <item>Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>. </item>
                     <item>Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise females not to breastfeed during treatment with WELIREG and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Advise male and female patients that WELIREG may impair fertility <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosage and Administration</content>
                  </paragraph>
                  <paragraph>Instruct patients to take their dose of WELIREG at the same time each day (once daily). Advise patients WELIREG can be taken with or without food. Each tablet should be swallowed whole <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left"/>
                     <tbody>
                        <tr styleCode="botrule">
                           <td align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section>
               <id root="40bd379e-1b16-4c87-a4f1-20ebf71a2fde"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: Merck Sharp &amp; Dohme LLC <br/>Rahway, NJ 07065, USA</paragraph>
                  <paragraph>For patent information: <linkHtml href="www.msd.com/research/patent">www.msd.com/research/patent</linkHtml>
                  </paragraph>
                  <paragraph>Copyright Â© 2021-2025 Merck &amp; Co., Inc., Rahway, NJ, USA, and its affiliates.<br/>All rights reserved.</paragraph>
                  <paragraph>uspi-mk6482-t-2504r003</paragraph>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section ID="MedGuide">
               <id root="9c5da019-01fd-41e6-aed6-600fc9f79a84"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 04/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE<br/>WELIREG<sup>Â®</sup>
                                 </content>
                                 <content styleCode="bold"> (Well-ih-reg)<br/>(belzutifan)<br/>tablets</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What is the most important information I should know about WELIREG?</content>
                              <br/>
                              <content styleCode="bold">WELIREG may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Low red blood cell counts (anemia).</content> Low red blood cell counts are common with WELIREG and can be severe. You may need a blood transfusion if your red blood cell counts drop too low. Your healthcare provider will do blood tests to check your red blood cell counts before you start and during treatment with WELIREG. Tell your healthcare provider if you get any symptoms of low red blood cell counts, including tiredness, feeling cold, shortness of breath, chest pain, or fast heartbeat.</item>
                                 <item>
                                    <content styleCode="bold">Low oxygen levels in your body.</content> WELIREG can cause low oxygen levels in your body that can be severe and may require you to stop treatment with WELIREG, receive oxygen therapy, or be hospitalized. Your healthcare provider will monitor your oxygen levels before you start and during treatment with WELIREG. Tell your healthcare provider or get medical help right away if you get symptoms of low oxygen in your body, including shortness of breath or increased heart rate.</item>
                                 <item>
                                    <content styleCode="bold">Harm to your unborn baby.</content> Treatment with WELIREG during pregnancy can cause harm to your unborn baby. <br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with WELIREG.</item>
                                       <item>You should use an effective form of non-hormonal birth control (contraception) during treatment with WELIREG and <content styleCode="bold">for 1 week</content> after your last dose.</item>
                                       <item>Birth control methods that contain hormones (such as birth control pills, injections, or transdermal system patches) may not work as well during treatment with WELIREG.</item>
                                       <item>Talk to your healthcare provider about birth control methods that may be right for you during treatment with WELIREG.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with WELIREG.<br/>
                                          <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                                       </item>
                                       <item>You should use effective birth control (contraception) during treatment with WELIREG and <content styleCode="bold">for 1 week</content> after your last dose.</item>
                                       <item>Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking WELIREG.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>See <content styleCode="bold">âWhat are the possible side effects of WELIREG?â </content>for more information about side effects.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What is WELIREG?</content>
                              </paragraph>
                              <paragraph>WELIREG is a prescription medicine used to treat adults with:</paragraph>
                              <list listType="unordered">
                                 <item>von Hippel-Lindau (VHL) disease who need treatment for a type of kidney cancer called renal cell carcinoma (RCC), tumors in the brain and spinal cord called central nervous system hemangioblastomas (CNS), or a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that do not require surgery right away.</item>
                                 <item>a type of kidney cancer called RCC with a clear cell component, that has spread (advanced RCC) following treatment with a programmed death-receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) cancer medicines.</item>
                              </list>
                              <paragraph>It is not known if WELIREG is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Before taking WELIREG, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have low red blood cell counts (anemia)</item>
                                 <item>are pregnant or plan to become pregnant. See <content styleCode="bold">âWhat is the most important information I should know about WELIREG?â</content>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if WELIREG passes into your breast milk. <content styleCode="bold">Do not</content> breastfeed during treatment with WELIREG and for 1 week after your last dose.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Â Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>Taking WELIREG with certain other medicines can affect each other and cause serious side effects.
                              </paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">How should I take WELIREG?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take WELIREG exactly as your healthcare provider tells you.</item>
                                 <item>Do not stop taking WELIREG or change your dose without talking to your healthcare provider.</item>
                                 <item>Take your prescribed dose of WELIREG 1 time a day, at the same time each day.</item>
                                 <item>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with WELIREG if you have certain side effects.</item>
                                 <item>Take WELIREG with or without food.</item>
                                 <item>Swallow WELIREG tablets whole. <content styleCode="bold">Do not</content> chew, crush, or split WELIREG tablets.</item>
                                 <item>If you miss a dose of WELIREG, take it as soon as possible on the same day. Then take your next dose of WELIREG at your regular time the next day. <content styleCode="bold">Do not</content> take extra tablets to make up for the missed dose.</item>
                                 <item>If you vomit after taking a dose of WELIREG, <content styleCode="bold">do not</content> take an extra dose. Take your next dose at your regular time the next day.</item>
                                 <item>If you take too much WELIREG, call your healthcare provider or go to the nearest emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of WELIREG?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">WELIREG may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>See <content styleCode="bold">âWhat is the most important information I should know about WELIREG?â</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of WELIREG in adults with VHL disease include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>tiredness</item>
                                 <item>increased creatinine (kidney function test)</item>
                                 <item>headache</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>dizziness</item>
                                 <item>increased blood sugar (glucose) levels</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of WELIREG in adults with advanced RCC include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>tiredness</item>
                                 <item>decreased white blood cells</item>
                                 <item>increased creatinine (kidney function test)</item>
                                 <item>muscle and joint pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>increased liver function tests</item>
                                 <item>decreased blood salts (sodium) levels</item>
                                 <item>increased blood potassium levels</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
											WELIREG may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
										</paragraph>
                              <paragraph>
											These are not all of the possible side effects of WELIREG.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
										</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">How should I store WELIREG?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Store WELIREG at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                                 <item>The WELIREG bottle has a child-resistant closure.</item>
                                 <item>The WELIREG bottle contains 2 desiccant canisters that help keep your medicine dry. <content styleCode="bold">Do not</content> eat the desiccant canisters.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep WELIREG and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of WELIREG.</content>
                              </paragraph>
                              <paragraph>
											Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use WELIREG for a condition for which it was not prescribed. Do not give WELIREG to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about WELIREG that is written for health professionals.
										</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in WELIREG?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> belzutifan</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide. The film-coating contains FD&amp;C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>Manufactured for: Merck Sharp &amp; Dohme LLC <br/>Rahway, NJ 07065, USA</paragraph>
                              <paragraph>For patent information: <linkHtml href="www.msd.com/research/patent">www.msd.com/research/patent</linkHtml>
                              </paragraph>
                              <paragraph>Copyright Â© 2021-2025 Merck &amp; Co., Inc., Rahway, NJ, USA, and its affiliates.<br/>All rights reserved.</paragraph>
                              <paragraph>usmg-mk6482-t-2504r004</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section ID="SPDP">
               <id root="4cc32fc0-972c-42f0-8502-84f885b792e1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 40 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 0006-5331-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Welireg<sup>TM</sup>
                        <br/>(belzutifan) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">40 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication<br/>Guide to each patient.</content>
                  </paragraph>
                  <paragraph>Each tablet contains 40 mg of belzutifan.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 Tablets</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 40 mg Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="welireg-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>